# EDGAR Filing Document

**Accession Number:** 0001427570
**File Stem:** 0001213900-25-087217
**Filing Date:** 2025-9
**Character Count:** 42895
**Document Hash:** 82faaf212bc3b814059cd2649bac4f86
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-087217.hdr.sgml**: 20250912

**ACCESSION NUMBER**: 0001213900-25-087217

**CONFORMED SUBMISSION TYPE**: 8-K/A

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250902

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250912

**DATE AS OF CHANGE**: 20250912

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vyome Holdings, Inc
- **CENTRAL INDEX KEY:** 0001427570
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37897
- **FILM NUMBER:** 251311596

**BUSINESS ADDRESS:**
- **STREET 1:** 1001 CALLE AMANECER
- **CITY:** SAN CLEMENTE
- **STATE:** CA
- **ZIP:** 92673
- **BUSINESS PHONE:** 949-429-6680

**MAIL ADDRESS:**
- **STREET 1:** 1001 CALLE AMANECER
- **CITY:** SAN CLEMENTE
- **STATE:** CA
- **ZIP:** 92673

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ReShape Lifesciences Inc.
- **DATE OF NAME CHANGE:** 20210621

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** OBALON THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20080220

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K/A**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): September 12, 2025 (September 2, 2025)**

**VYOME HOLDINGS, INC.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **1-37897** | **26-1828101** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (IRS Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **Harvard Square, One Mifflin Place, Suite 400**<br> **Cambridge, MA** | **02138** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (973) 832-8147**

**<u>Not Applicable</u>**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| Title of each class | Name of each exchange on which registered |
| Common stock, par value $0.001 per share HIND | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Explanatory Note**

This Amendment No. 1 to the Current Report on Form 8-K of Vyome Holdings, Inc. filed with the Securities and Exchange Commission on September 2, 2025 (the "Original Report") is being filed solely to amend Exhibit 99.3 to the Original Report to correct certain calculations that were erroneously computed. The corrected Unaudited Pro Forma Condensed Combined Financial Statements is filed as Exhibit 99.1 to this Amendment No. 1.

Except as described above, this Amendment No. 1 does not modify or update any other disclosures in the Original Report and does not reflect any events occurring after the filing of the Original Report.

**Item 9.01. Financial Statements and Exhibits.**

*(d) Exhibits.*

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Unaudited Pro Forma Condensed Combined Financial Statements](ea025703201ex99-1_vyome.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **VYOME HOLDINGS, INC.** | **VYOME HOLDINGS, INC.** |
| September 12, 2025 | By: | */s/ Venkat Nelabhotla* |
|  | Name: | Venkat Nelabhotla |
|  | Title: | President & Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**RESHAPE AND VYOME UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS**

On July 8, 2024, ReShape, Vyome, and Merger Sub, entered into the Merger Agreement ("Merger"). Pursuant to the Merger Agreement, and subject to the satisfaction or waiver of the conditions specified therein, Merger Sub shall be merged with and into Vyome, with Vyome surviving as a subsidiary of ReShape. Closing of the Merger occurred on August 14, 2025 (the Effective Time").

At the Effective Time of the Merger, each Vyome Share issued and outstanding immediately prior to the Effective Time (other than the shares that are owned by ReShape, Vyome, or Merger Sub and shares that will be subject to a put-call option agreement with certain stockholders of Vyome located in India) will be converted into the right to receive a number of fully paid and non-assessable ReShape Shares according to an Exchange Ratio determined at least 10 calendar days prior to the ReShape Special Meeting that will result in the holders of such Vyome Shares, together with holders of Vyome securities convertible into Vyome Shares, owning approximately 92.4% of the outstanding ReShape Shares on a fully-diluted basis immediately after the Effective Time.

The Merger Agreement provides that, at the Effective Time, each outstanding stock option or other equity award to purchase capital stock of Vyome will be converted into equity awards to purchase a number of ReShape Shares equal to the number of shares of Vyome Common Stock issuable upon exercise of such Vyome equity award multiplied by the Exchange Ratio, with an exercise price, in the case of warrants and stock options, equal to the exercise price of such Vyome option divided by the Exchange Ratio. The exercise price and number of shares will be determined in a manner consistent with the requirements of Section 409A, and as applicable, Section 424(a) of the Internal Revenue Code, and the applicable regulations promulgated thereunder.

Simultaneously with the execution of the Merger Agreement, ReShape entered into the Asset Purchase Agreement with Biorad ("Asset Sale"). Pursuant to the Asset Purchase Agreement, and subject to the satisfaction or waiver of the conditions specified therein, ReShape will sell substantially all of its assets (excluding cash) to Biorad, and Biorad will assume substantially all of ReShape's liabilities, for a purchase price of approximately $1.6 million in cash, net of adjustment based on ReShape's actual accounts receivable and accounts payable at the closing compared to such amounts as of March 31, 2024. Biorad is party to a previously disclosed exclusive license agreement, dated September 19, 2023, with ReShape for ReShape's Obalon® Gastric Balloon System. The proforma financials below include the anticipated impact the Asset Sale might have on our combined financial information.

Simultaneously with the execution of the Merger Agreement, ReShape, Vyome, and Vyome's wholly- owned subsidiary Vyome Therapeutics Limited ("Vyome India") entered into agreements with certain existing accredited investors, pursuant to which the investors have agreed to purchase of approximately $7.30 million in securities of ReShape, Vyome and Vyome India (the "Concurrent Financing"), of which approximately $660,000 has been received in the form of bridge notes through the Effective Time. As part of the Concurrent Financing, certain accredited investors have agreed to purchase up to $5.7 million in shares of common stock of the combined company and approximately $930,000 in shares of shares in Vyome India, immediately following completion of the Merger. The price per share for the common stock of the Combined Company will be calculated as a 30% discount to the price per share of the common stock for the agreed-upon valuation of the combined company obtained by dividing (i) the sum of $130,000,000 and ReShape Net Cash by (ii) the sum of Total ReShape Outstanding Shares and Vyome Merger Shares. Simultaneously with the execution of the subscription agreements, Vyome entered into a securities purchase agreement with each investor pursuant to which Vyome issued to each investor a convertible promissory note in the principal amount equal to approximately 5% of such investor's total agreed upon investment amount, which convertible notes will bear interest at 8% per annum and immediately prior to completion of the Merger will convert into a number of shares of common stock of the combined company equal to 100% of the outstanding principal and interest of the Note divided by the price per share of common stock to be purchased in the financing as set forth above. ReShape and the investors are executing and delivering the subscription agreements in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended, and contemporaneously with the sale of the shares of common stock will execute and deliver a registration rights agreement in substantially the form attached to the subscription agreement.

The pro forma ownership percentages of the ReShape and Vyome stockholders of the Combined Company of 8.12% and 91.88%, respectively, subject to adjustment as described in this proxy/information statement-prospectus, are prior to taking into account the Concurrent Financing. Therefore, the actual ownership percentages will be different following the completion of the Concurrent Financing, and, because certain of the investors in the Concurrent Financing are existing Vyome stockholders, the actual ownership percentage of the ReShape stockholders will be decreased compared to that of the Vyome stockholders after the closing of the Concurrent Financing.

The following unaudited pro forma condensed combined financial statements have been prepared to illustrate the estimated effects of the Merger. The ReShape and Vyome unaudited pro forma combined balance sheet data combine the ReShape and Vyome historical balance sheets at June 30, 2025. The ReShape and Vyome unaudited pro forma condensed combined statements of operations data assume that the Asset Sale and the Merger closed as of January 1, 2024, and combine the historical results of operations of ReShape and Vyome for the six months ended June 30, 2025. The unaudited pro forma condensed combined financial information was prepared pursuant to the rules and regulations of Article 11 of SEC Regulation S-X, as amended.

The Merger is accounted for as a reverse recapitalization under U.S. GAAP since ReShape will have nominal operations and assets at the time of the closing of the Merger. Vyome was determined to be the accounting acquirer based upon the terms of the Merger and other factors including (i) holders of such Shares, together with holders of Vyome securities convertible into Vyome Shares are expected to own 91.62% of the outstanding ReShape Shares on a fully-diluted basis immediately after the Effective Time, (ii) Vyome will hold substantially all of the board seats of the combined company and (iii) Vyome's management will hold all key positions in the management of the combined company.

The unaudited pro forma condensed combined financial statements are based on and should be read in conjunction with both Vyome and ReShape Management's Discussion and Analysis of Financial Condition and Results of Operations and Vyome and ReShape's financial statements and related notes appearing elsewhere in this proxy/information statement-prospectus.

The unaudited pro forma condensed combined financial statements have been prepared for illustrative purposes only and are not necessarily indicative of the consolidated financial position or results of operations that would have been realized had the Merger occurred as of the dates indicated, nor is it meant to be indicative of any future consolidated financial position or future results of operations that the Combined Company will experience. The unaudited pro forma condensed combined financial statements combine the historical statements of ReShape and Vyome, the Concurrent Financing undertaken, financings done by ReShape in the third quarter of 2025, and reflects the impact of the sale of substantially all of ReShape's assets and liabilities to Biorad, for the period on a pro forma basis along with the Merger and related transactions, summarized below. The pro forma adjustments included in the accompanying unaudited pro forma condensed combined financial statements are based on currently available data and assumptions that management of ReShape believes are reasonable.

**UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS**

**FOR THE SIX MONTHS ENDED JUNE 30, 2025**

**(Amounts in thousands, except per share data)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Historical** | **Historical** | | | | |
|  | **6 months** | **6 months** | | | | |
|  | **June 30,**<br>**2025** | **June 30,**<br>**2025** | | | | |
|  | **Vyome** | **Reshape** |<br>**Vyome**<br>**Pro Forma**<br>**Adjustments**<br>**Note 6** |<br>**ReShape**<br>**Pro Forma**<br>**Adjustments**<br>**Note 6** |<br>**Total**<br>**Pro Forma**<br>**Adjustments** |<br><br>**Pro Forma**<br>**Combined** |
| Revenue | $249 | $2355 | $— | $(2355) **B** | $(2355) | $249 |
| Cost of revenue | 70 | 1075 |  | (1075) **B** | (1075) | 70 |
| Gross profit | 179 | 1280 |  | (1280) | (1280) | 179 |
| Operating expenses: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Selling, general and Administrative | 532 | 4368 |  | (4368) **B** | (4368) | 532 |
| &nbsp;&nbsp;&nbsp;Research and development | 170 | 840 |  | (840) **B** | (840) | 170 |
| &nbsp;&nbsp;&nbsp;Transaction costs |  | 1043 |  | (1043) **B** | (1043) |  |
| &nbsp;&nbsp;&nbsp;Impairment of long-lived assets |  |  |  | — **B** |  |  |
| Total operating expenses | 702 | 6251 |  | (6251) | (6251) | 702 |
| Operating loss | (523) | (4971) |  | 4971 | 4971 | (523) |
| Other expense (income), net: |  |  |  |  |  |  |
| Interest expense (income), net | 111 | 21 | (111) **E** | (21) **B** | (132) |  |
| Gain on extinguishment of debt |  | (24) |  | 24 | 24 |  |
| Gain on changes in fair value of liability warrants |  | (3663) |  | 3663 **B** | 3663 |  |
| Loss on change in fair value of convertible debt | (30) |  | 30 **E** |  | 30 |  |
| Loss on foreign currency exchange |  | (49) |  | 49 **B** | 49 |  |
| Other, net | (1) | (114) |  | 114 **B** | 114 | (1) |
| Loss before income tax provision | (603) | (1142) | 81 | 1142 | 1223 | (522) |
| Income tax benefit |  | 14 |  | (14) **B** | (14) |  |
| Net loss attributable to common shareholders | $(603) | $(1156) | $81 | $1156 | $1237 | $(522) |
| Net loss per share - basic and diluted: | $(1562.18) | $(2.24) |  |  |  | $(0.07) |
| Weighted-average shares used to compute net loss per share attributable to ordinary shareholders | 386 | 515566 |  |  |  | 7191409 |

---

*See accompanying Notes to Unaudited Pro Forma Condensed Combined Financial Information.*

**UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET AS OF JUNE 30, 2025**

**(Amounts in thousands, except per share data)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  |<br>**June 30,**<br>**2025** |<br>**June 30,**<br>**2025** | | | | | |
|  | **Vyome** | **ReShape** | **Vyome**<br>**Pro Forma**<br>**Adjustments**<br>**Note 5** | <br>**Note** | **ReShape**<br>**Pro Forma**<br>**Adjustments**<br>**Note 5** |<br>**Total**<br>**Pro Forma**<br>**Adjustments** |<br>**Pro Forma**<br>**Combined** |
| **ASSETS** |  |  |  |  |  |  |  |
| Current assets: |  |  |  |  |  |  |  |
| Cash and cash equivalents | $383 | $4123 | $5438 | **D, G** | $(4123) **A** | $1315 | $5821 |
| Restricted cash |  | 100 |  |  | (100) **B** | (100) |  |
| Accounts and other receivables, net | 2 | 775 |  |  | (775) **B** | (775) | 2 |
| Inventory |  | 2552 |  |  | (2552) **B** | (2552) |  |
| Prepaid expenses and other | 89 | 1312 |  |  | (1312) **B** | (1312) | 89 |
| Total current assets | 474 | 8862 | 5438 |  | (8862) | (3424) | 5912 |
| Property and equipment, net | 54 | 30 |  |  | (30) **B** | (30) | 54 |
| Operating lease right-of-use assets | 45 | 79 |  |  | (79) **B** | (79) | 45 |
| Deferred tax asset, net |  | 28 |  |  | (28) **B** | (28) |  |
| Other intangible assets, net | 314 |  |  |  |  |  | 314 |
| Other assets | 738 | 29 | (111) |  | (29) **B** | (140) | 627 |
| **TOTAL ASSETS** | $1625 | $9028 | $5327 |  | $(9028) | $(3701) | $6952 |
| **LIABILITIES, REDEEMABLE CONVERTIBLE PREFERENCE SHARES AND SHAREHOLDERS' (DEFICIT) EQUITY** | **LIABILITIES, REDEEMABLE CONVERTIBLE PREFERENCE SHARES AND SHAREHOLDERS' (DEFICIT) EQUITY** | **LIABILITIES, REDEEMABLE CONVERTIBLE PREFERENCE SHARES AND SHAREHOLDERS' (DEFICIT) EQUITY** | **LIABILITIES, REDEEMABLE CONVERTIBLE PREFERENCE SHARES AND SHAREHOLDERS' (DEFICIT) EQUITY** | **LIABILITIES, REDEEMABLE CONVERTIBLE PREFERENCE SHARES AND SHAREHOLDERS' (DEFICIT) EQUITY** | **LIABILITIES, REDEEMABLE CONVERTIBLE PREFERENCE SHARES AND SHAREHOLDERS' (DEFICIT) EQUITY** | **LIABILITIES, REDEEMABLE CONVERTIBLE PREFERENCE SHARES AND SHAREHOLDERS' (DEFICIT) EQUITY** | **LIABILITIES, REDEEMABLE CONVERTIBLE PREFERENCE SHARES AND SHAREHOLDERS' (DEFICIT) EQUITY** |
| Accounts payable | $869 | $1346 | $— |  | $(1346) **B** | $(1346) | $869 |
| Accrued and other liabilities | 1074 | 1586 |  |  | (1586) **B** | (1586) | 1074 |
| Warranty liability |  | 163 |  |  | (163) **B** | (163) |  |
| Due to affiliates | 170 |  |  |  |  |  | 170 |
| Convertible debt | 4034 |  | (4034) | **E** |  | (4034) |  |
| Promissory notes - ReShape | 424 |  | (424) |  |  | (424) |  |
| Operating lease liabilities, current | 30 | 104 |  |  | (104) **B** | (104) | 30 |
| Total current liabilities | 6601 | 3199 | (4458) |  | (3199) | (7657) | 2143 |
| Operating lease liabilities, noncurrent | 17 |  |  |  | — **B** |  | 17 |
| **TOTAL LIABILITIES** | 6618 | 3199 | (4458) |  | (3199) | (7657) | 2160 |
| Preferred stock | 3 |  |  | **F** |  |  | 3 |
| Common stock | 1 |  |  |  | — **C** |  | 1 |
| Additional paid-in capital | 51085 | 649798 | 11493 | **D, E** | (649798) **C** | (638305) | 62578 |
| Accumulated other comprehensive loss | (57) | (109) |  |  | 109 **B** | 109 | (57) |
| Accumulated deficit | (56025) | (643860) | (1708) |  | 643860 **C** | 642152 | (57733) |
| Total shareholders' (deficit) equity / stockholders' (deficit) equity | (4993) | 5829 | 9785 |  | (5829) | 3956 | 4792 |
| Total liabilities, redeemable convertible preference shares and stock, and shareholders' (deficit) equity | $1625 | $9028 | $5327 |  | $(9028) | $(3701) | $6952 |

---

*See accompanying Notes to Unaudited Pro Forma Condensed Combined Financial Information.*

**Notes to the Unaudited Pro Forma Condensed Combined Financial Statements**

1. Description of the Merger

On July 8, 2024, ReShape, Vyome, and Merger Sub, entered into the Merger Agreement. Pursuant to the Merger Agreement, and subject to the satisfaction or waiver of the conditions specified therein, Merger Sub shall be merged with and into Vyome, with Vyome surviving as a subsidiary of ReShape. Closing of the Merger occurred on August 14, 2025 (the Effective Time").

At the Effective Time of the Merger, each Vyome Share issued and outstanding immediately prior to the Effective Time (other than the shares that are owned by ReShape, Vyome, or Merger Sub and shares that will be subject to a put-call option agreement with certain stockholders of Vyome located in India) will be converted into the right to receive a number of fully paid and non-assessable ReShape Shares according to an Exchange Ratio determined at least 10 calendar days prior to the ReShape Special Meeting that will result in the holders of such Vyome Shares, together with holders of Vyome securities convertible into Vyome Shares, owning 92.4% of the outstanding ReShape Shares on a fully-diluted basis immediately after the Effective Time.

The Merger Agreement provides that, at the Effective Time, each outstanding stock option or other equity award to purchase capital stock of Vyome will be converted into equity awards to purchase a number of ReShape Shares equal to the number of shares of Vyome Common Stock issuable upon exercise of such Vyome equity award multiplied by the Exchange Ratio, with an exercise price, in the case of stock options, equal to the exercise price of such Vyome option divided by the Exchange Ratio. The exercise price and number of shares will be determined in a manner consistent with the requirements of Section 409A, and as applicable, Section 424(a) of the Internal Revenue Code, and the applicable regulations promulgated thereunder.

In connection with the transactions contemplated by the Merger Agreement ReShape entered into an agreement with a majority of the holders of its outstanding Series C Preferred Stock pursuant to which the holders of the Series C Preferred Stock agreed, subject to and contingent upon the completion of the Merger and the Asset Sale, to reduce the liquidation preference of the Series C Preferred Stock from $26.2 million to the greater of (i) $1 million, (ii) 20% of the purchase price paid for the Asset Sale and (iii) the excess of ReShape's actual net cash at the effective time of the Merger over the minimum net cash required as a condition to the closing of the Merger as set forth in the Merger Agreement and described below (the "Series C Amendment"). Under the terms of the Series C Amendment, the Series C Preferred Stock would automatically terminate at the effective time of the Merger and would be paid the agreed upon reduced liquidation preference.

In the Merger, ReShape stockholders will continue to own and hold their existing ReShape Shares. Each ReShape restricted stock unit award that is outstanding and unvested immediately prior to the Effective Time, shall become fully vested as of immediately prior to, and contingent upon, the Effective Time. Each ReShape stock option that is outstanding, whether vested or unvested, immediately prior to the Effective Time was canceled and terminated without any payment.

2. Basis of Presentation

The unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11, as amended by SEC Final Rule Release No. 33-10786, *Amendments to Financial Disclosures About Acquired and Disposed Businesses*. In accordance with Release No. 33-10786, the unaudited condensed combined pro forma balance sheet and statements of operations reflect transaction accounting adjustments, as well as other adjustments deemed to be directly related to the Proposed Transactions, irrespective of whether or not such adjustments are deemed to be recurring.

*Reverse Stock Split*

On August 13, 2025, at the commencement of trading, ReShape effected a 1-for-4 reverse stock split. Accordingly, all share and per share amounts presented in the accompanying pro forma financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the reverse stock split. No fractional shares were issued in connection with the reverse stock split.

 

On May 9, 2025, at the commencement of trading, ReShape effected a 1-for-25 reverse stock split. Accordingly, all share and per share amounts presented in the accompanying pro forma financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the reverse stock split. No fractional shares were issued in connection with the reverse stock split.

 

On September 23, 2024, at the commencement of trading, ReShape effected a 1-for-58 reverse stock split. Accordingly, all share and per share amounts presented in the accompanying pro forma financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect the reverse stock split. No fractional shares were issued in connection with the reverse stock split.

For accounting purposes, Vyome is considered to be the acquiring company and the Merger will be accounted for as a reverse recapitalization of ReShape by Vyome because, at the time of the Merger, ReShape is expected to have nominal assets and operations as a result of the closing of the Asset Sale.

Under reverse recapitalization accounting, the financial statement of the combined entity will represent a continuation of the financial statements of Vyome. No goodwill or intangible assets will be recognized. The unaudited pro forma condensed combined financial information of Vyome reflects the operations of the acquirer for accounting purposes together with the shares held by the stockholders of the legal acquirer and the issuance of the shares to be held by the accounting acquirer. The pro forma adjustments represent management's best estimates and are based upon currently available information and certain assumptions that management believes are reasonable under the circumstances.

The unaudited pro forma information is not necessarily indicative of what the Combined Company's financial position or results of operations would have been had the Merger been completed on the dates indicated. In addition, the unaudited pro forma condensed combined financial information does not purport to project the future financial position or operating results of the Combined Company.

There were no material transactions between ReShape and Vyome during the periods presented in the unaudited pro forma condensed combined financial statements, other than the promissory notes issued by Vyome to ReShape in the principal amount of $600,000.

3. Accounting Policies and Reclassification Adjustments

The accounting policies used in the preparation of this unaudited pro forma condensed combined financial information are those set out in Vyome's consolidated financial statements as of and for the year ended December 31, 2024. Based on Vyome management's assessment to date, the accounting policies of ReShape are similar in all material respects to Vyome's accounting policies.

The Combined Company may, as a result, identify additional differences between the accounting policies of the two companies which, when conformed, could have a material impact on the combined consolidated financial statements.

Certain reclassifications have been made ReShape's financial statements to conform to classifications used by Vyome.

4. Share Issuances

At the Effective Time, each Vyome Share (other than the shares that are owned by ReShape, Vyome, or Merger Sub and shares that will be subject to a put-call option agreement with certain Indian stockholders of Vyome and its' subsidiary in India) will be converted into the right to receive a number of ReShape Shares, according to a ratio determined at least 10 days prior to the ReShape Special Meeting that will result in the holders of such Vyome Shares (not including the investors in the Concurrent Financing) owning 85.5% of the outstanding Combined Company Shares immediately after the effective time of the Merger, subject to adjustment based on whether ReShape's net cash is greater than or less than $5 million and assuming the Concurrent Financing occurs. Based on the number of shares outstanding as of the Effective Time, and ReShape's net cash at such time, the Exchange Ratio was calculated to be 0.6244 ReShape Shares for each share of Vyome common stock outstanding or underlying the Vyome preferred stock, without giving effect to the proposed reverse stock split of ReShape Shares described in this proxy/information statement- prospectus.

Based on the closing price per share of ReShape Shares on The Nasdaq Capital Market on the Effective Date of $8.96, the date on which the assumed Exchange Ratio of 0.6244 ReShape Shares for each Vyome Share was calculated, the estimated value of each Vyome Share in the Merger would be approximately $15.74. The market price of the ReShape Shares is subject to general price fluctuations in the market for publicly traded equity securities and has experienced volatility in the past and may vary significantly from the date of the ReShape Special Meeting.

The following table shows the shares outstanding pre- and post-Merger for purposes of this pro forma financial statement, as adjusted for the share exchange ratio.

---

| | | | |
|:---|:---|:---|:---|
|  | **Shares Issued** | **Entitlement Shares in Combined Company to honor put/call option agreement using Vyome-USA and Vyome-India shares** | **Fully <br> Diluted <br> shares<br> outstanding** |
| Shares of Reshape, post reverse stock split | 674157 |  | 674157 |
| Shares to be issued to former Vyome debtholders, common and preferred shareholders, penny warrants (which will be exercised and convert to common shares prior to Merger date) for participation in Concurrent financing - a portion of which are subject to the put/call option agreement | 4272632 | 825451 | 5098083 |
| Underlying entitlement of common Shares in the Combined company for former Indian resident shareholders for participation in Concurrent Financing by putting money in Vyome-India- subject to the put/call option agreement | - | 800361 | 800361 |
|  | 4946789 | 1625812 | 6572601 |
| Shares to be issued in Concurrent Financing only for those amounts that come at merger closing in Combined company and the entitlement shares thru a put/call option agreement using the shares of Vyome's subsidiary as a result of such an investment at merger closing in Vyome's India subsidiary | 618808 | - | 618808 |
| &nbsp;&nbsp;&nbsp;**Post-merger, proforma shares outstanding in Combined company and Vyome subsidiary in India** | 5565597 | 1625812 | 7191409 |

---

The following table shows the post-split fully diluted shares outstanding for purposes of this pro forma financial statement:

---

| | | |
|:---|:---|:---|
|  | **Shares** | **Shares** |
| Post-merger Vyome stock options outstanding |  | 1725220 |
| Post-merger, proforma shares outstanding | | 7,191,409 |
| Fully diluted shares outstanding | | 8,916,629 |

---

As a result of the conversion of the Vyome Convertible Debt, preferred stock and Bridge Financing to common shares prior to the Merger, Vyome will have approximately 4.3 million common shares outstanding and 1.6 million shares subject to the put/call option described below.

ReShape completed a 1-for4 reverse stock split in August 2025, 1-for-58 reverse stock split in September 2024 and a 1-for-25 reverse stock split in May 2025, prior to the Merger such that approximately 0.7 million common shares will be outstanding. In connection with the Merger and pursuant to the Exchange ratio, ReShape will issue approximately 4.2 million shares to former Vyome shareholders. At the Merger date, there will be approximately 0.8 million entitled shares of the Combined Company which are subject to put/ call option agreement using Vyome shares owned by certain Indian resident shareholders. At the Merger date, there will be 0.9 million entitled shares of the Combined Company which are subject to put/call Option agreement using Vyome' subsidiary shares owned by certain Indian resident shareholders. At the Merger date, there will be Vyome stock options outstanding for the purchase of approximately 1.8 million shares of common stock.

Post Merger, the combined company issued approximately 0.6 million shares of common stock from the Concurrent Financing, raising expected gross proceeds of approximately $6.6 million. Also, as part of Concurrent financing for the investments made by certain India resident shareholders in Vyome's subsidiary in India, there will be approximately 0.1 million entitled shares of the Combined Company which are subject to put/call option agreement using this investment-related shares in Vyome's subsidiary in India.

Based on ReShape's closing share price of $15.68 on the Effective Time, the value of shares to be issued in connection with the Merger will be approximately $92.5 million. This amount reflects the following:

● Shares to be issued to former Vyome debtholders, common and preferred shareholders, penny warrants (which will be exercised and convert to common shares prior to Merger date) for participation in Concurrent financing — a portion of which are subject to the put/call option agreement.

● Underlying entitlement of common shares in the combined company for former Indian resident shareholders for participation in Concurrent Financing by putting money in Vyome-India-subject to the put/call option agreement

The value of shares to be issued post Merger, in connection with the Concurrent Financing, will be approximately $9.7 million. This amount reflects the following:

● Shares to be issued in Concurrent Financing only for those amounts that come at merger closing in combined company and the entitlement shares thru a put/call option agreement using the shares of Vyome's subsidiary as a result of such an investment at merger closing in Vyome's India subsidiary

5. Notes to Unaudited Pro Forma Condensed Combined Balance Sheet — Pro Forma Adjustments

***ReShape Pro Forma Adjustments:***

 ****

**A:** The proceeds from the sales of the ReShape operating business to BioRad will be used primarily pay costs related to Merger costs, employee costs and other matters, and the $1.0 million payment to the ReShape Series C preferred shareholders. The tables below reflect adjustments to cash and cash equivalents as of June 30, 2025:

---

| | |
|:---|:---|
|  | **Amount** |
|  | **(in thousands)** |
| Change in control bonus – paid to Preferred Series C shareholders (1) | $(1000) |
| Contingent success fee (2) | (1500) |
| Cash paid for third party professional fees (3) | (680) |
| Cash paid for PTO and Severance (4) | (1518) |
| Cash paid for D&O Tail (5) | (782) |
| Cash proceeds from Asset Sale to Biorad (6) | 1600 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A/R-A/P Adjustment (7) | (468) |
| Proceeds from ATM agreement from July 1, 2025 to Effective Date(8) | 225 |
| &nbsp;&nbsp;&nbsp;Total pro forma adjustment to cash and cash equivalents | $(4123) |

---

(1) Reflects
 payment of $1.0 million to Preferred Series C shareholders related to change in control payout
 under the Series C purchase agreements.

(2) Reflects
 contingent success fee to be paid to Maxim upon completion of transaction.

(3) Reflects
 costs paid related to the Merger transaction. Amounts include printer, legal, and audit fees.

(4) Reflects
 severance, termination, or similar payments due to certain current and former employees.

(5) Reflects
 costs for the "tail" D&O insurance policies paid in accordance with the Merger
 Agreement.

(6) Reflects
 cash proceeds from the Asset Sale to Biorad ReShape will sell substantially all of its assets
 (excluding cash) to Biorad, and Biorad will assume substantially all of ReShape's liabilities,
 for a purchase price of $1.6 million in cash.

(7) Reflects payment for the net settlement of remaining accounts payable
and accounts receivable from ReShape at closing of the Merger.

(8) Reflects
 funds raised through the ReShape ATM facility from July 1, 2025 to the Effective Time.

**B:** Reflects the elimination of ReShape's assets and liabilities as of June 30, 2025 to the standalone operating entity, as Vyome is not assuming any of ReShape's assets or liabilities in the transaction. These adjustments also reflect the impact of the sale of substantially all ReShape's assets and liabilities to BioRad, and the elimination of the operating accounts of ReShape as a result of the Asset Sale.

**C:** To record the (i) elimination of ReShape's historical equity, (ii) issuance of ReShape Shares to Vyome stockholders upon closing of the Merger, (iii) transaction costs associated with the Merger, and (iv) impact of reverse capitalization transaction.

---

| | |
|:---|:---|
|  | **Amount** |
|  | **(in thousands)** |
| Elimination of Reshape's historical APIC balance | $(649798) |
| Reverse Recapitalization of ReShape Equity | 2420 |
| Change in control bonus - paid to Preferred Series C shareholders | (1000) |
| Proceeds from ATM | 225 |
| Payment of third party professional fees | (680) |
| Payment of contingent success fee | (1500) |
| Payment of PTO and Severance | (1518) |
| Payment of D&O Tail | (782) |
| Gain from Asset Sale to Biorad | 2835 |
| Total pro forma adjustments to APIC | $(649798) |

---

---

| | |
|:---|:---|
|  | **Amount** |
|  | **(in thousands)** |
| Elimination of Reshape's historical accumulated deficit | $643715 |
| Payment of other miscellaneous transaction costs | 145 |
| &nbsp;&nbsp;&nbsp;Total pro forma adjustment to accumulated deficit | $643860 |

---

***Vyome Pro Forma Adjustments:***

 ****

**D:** Through August 2024, Vyome continued its compulsory note payable bridge offering ("Bridge Financing"), which could be raised prior to the Merger. The term of these Bridge Financing notes is similar to the convertible notes issued by Vyome since 2020 and may be issued by either the Vyome US parent company or the Vyome subsidiary in India. Through June 30, 2025, the Vyome US parent company raised approximately $660,000 of these Bridge Financing notes which, along with accrued interest, will convert immediately prior to the Merger at a 25% discount to the 30% discount to the valuation determined through the Merger. The Bridge Financing notes issued by the Vyome subsidiary in India of approximately $86,000 have the same terms and are also subject to a "put/call option" — see discussion below. Immediately prior to the Merger, all but the notes subject to the put/call option from such Bridge Financing notes were converted into shares of common stock of Vyome.

In July 2024, Vyome commenced a debt and equity offering ("Concurrent Financing") of up to $10 million to be issued by Vyome. It's subsidiary in India and the combined company immediately after completion of Merger. The investors in the Concurrent Financing were able to invest in a one-year 8% compulsory convertible note issued by either Vyome or the Vyome subsidiary in India or shares of either the combined company or Vyome's subsidiary entity in India. Certain investors also received a warrant to purchase shares of the combined company's common stock at $0.001 per share. The Company has received commitments of approximately $6.5 million of the combined company common stock and has received commitments of approximately $1.0 million of common stock of the Vyome subsidiary in India and are also subject to a "put/call option" — see discussion below — under such Concurrent Financing.

**E:** Vyome's outstanding principal amount of their Convertible Notes including any unpaid accrued interest shall automatically convert in whole into Vyome's common shares immediately prior to the Merger date at a conversion price equal to the assumed pre-Merger valuation per share multiplied by 0.75 and then multiplied by 70%. Since this conversion is deemed to have happened at the beginning of each period presented, the recorded interest expense and changes in the fair value of the convertible notes is eliminated from the presentation of the pro forma results of operations.

**F**: Each share of Vyome's preferred stock is mandatorily convertible into shares of Vyome common stock at the conversion price as defined in the shareholders' agreement immediately prior to the Merger date. However, certain India-based shareholders will not convert their preferred shares into common shares due to regulatory restrictions. Instead, they will receive shares subject to the put/call option — see below.

The shares issued by Vyome subsidiary in India and certain shares owned by Indian resident shareholders are subject to put and call option agreements whereby the Combined Company can call the shares at the quoted market value on such date called by the combined company, or the shareholders can put their shares to the combined company either for exchange, subject to certain conditions, of the equivalent number of combined company shares or for a specified amount of cash subject to explicit approval of the board of directors of the combined company.

**G:** Vyome's estimated transaction costs for the Merger related expenses is approximately $1.7 million.

**6.** **Notes to Unaudited Pro Forma Condensed Combined Statement of Operations — Pro Forma Adjustments** 

E: — Refer to Note E above for adjustments related to Vyome's convertible debt.

**7.** **Pro Forma Weighted Average Shares (Basic and Diluted)** 

Basic net loss per share of common stock is computed by dividing net loss by the weighted average number of vested shares of common stock outstanding during the period. Diluted net income per share of common stock is computed by dividing net income by the weighted average number of common and dilutive common-equivalent shares outstanding during each period. The exchanged Vyome stock options for the issuance of 1,725,220 shares of common stock were excluded from the calculation of weighted average dilutive shares of common stock because their inclusion would have been anti-dilutive.

The below table reflects the Pro Forma loss per share computation for the six months ended June 30, 2025.

---

| | |
|:---|:---|
|  | **Pro Forma**<br>**For the Six**<br>**Months Ended <br> June 30,<br> 2025** |
| **Numerator for basic earnings per share calculation:** |  |
| Pro Forma loss (for basic and diluted EPS) | $(522) |
| **Denominator for basic and diluted earnings per share calculation:** |  |
| Weighted-average ReShape's outstanding shares | 674157 |
| Outstanding shares of the Combined Company and entitlement Shares in Combined Company to honor put/call option agreement with Vyome USA and Vyome India as part of the merger and Concurrent Financing | 6517252 |
| **Pro Forma weighted average shares (basic and diluted)** | 7191409 |
| **Pro Forma earnings per share (basic and diluted)** | $(0.07) |

---